# Glooko

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/glooko

- Industry: Healthcare IT
- Headquarters: Palo Alto, US
- Website: www.glooko.com
- Total disclosed funding: $201M
- Latest round: Series F (Oct 10, 2024)
- Investors on record: 13

## About

Glooko AB is a technology company based in the US that specializes in connected care solutions for diabetes management, providing healthcare providers with tools to monitor and analyze patient data effectively.Founded in 2010 by Yogen Dalal and headquartered in Palo Alto, US, Glooko Inc. focuses on delivering digital healthcare solutions for diabetes. The company has completed a total of 8 funding deals, with the most recent being a Series F funding round in October 2024, raising USD 100 mn led by Georgian, while also featuring contributions from Health Catalyst Capital Management and Canaan Partners. Glooko has raised a total of USD 100 mn to date and currently holds a valuation of USD 420.875 mn.Glooko specializes in connected care solutions for diabetes management, offering a comprehensive platform that includes remote patient monitoring, data integration, and analytics. Their core product enables healthcare providers to track and manage patients' glucose levels effectively, facilitating improved glycemic control through real-time data access. Glooko's services are primarily targeted toward healthcare providers, including hospitals, diabetes care clinics, and health plans. The company’s products are currently available in several international markets, including the United States, Germany, Spain, and France.In 2022, Glooko reported a revenue of USD 7,908,974.80 with an EBITDA of USD -4,448,153.40. The company operates on a subscription-based revenue model, generating income through partnerships with healthcare providers and organizations that utilize their platform.In October 2024, Glooko Inc. raised USD 100 mn in Series F funding, which will be utilized to accelerate the global product expansion of its digital healthcare platform and enhance its life sciences initiatives for diabetes management. The company plans to enter new geographic markets and regions in the coming years as part of its strategy to expand its reach.

## Funding rounds

- Series F, Oct 10, 2024, $100M — Canaan Partners, Georgian, Health Catalyst Capital Management
- Series D, Mar 4, 2021, $30M — Mayo Clinic Ventures, Canaan Partners, Georgian, Novo Nordisk A/S, Insulet Corporation, Health Catalyst Capital Management
- Series C, Jun 28, 2017, $35M — Canaan Partners, Georgian, Medtronic Ventures, Mayo Clinic, Social Capital, Insulet Corporation, Samsung NEXT Ventures
- Series B, Sep 13, 2016, $8M — Canaan Partners, Samsung Venture Investment, Social Capital
- Series B, Mar 17, 2015, $17M — Canaan Partners, Samsung Venture Investment, Medtronic Ventures, Social Capital
- Series A, Jan 8, 2014, $7M — Samsung Venture Investment, Social Capital, LifeForce Capital
- Series A, Jan 30, 2012, $3.5M — Social Capital
- Seed, Dec 20, 2010, $0.9M — Social Capital, Xtreme Labs Inc.

## Investors

- Social Capital (https://capitalatlas.ai/funds/social-capital) — Seed, Series A, Series B, Series C
- Xtreme Labs Inc. — Seed
- Samsung Venture Investment (https://capitalatlas.ai/funds/samsung-venture-investment) — Series A, Series B
- LifeForce Capital (https://capitalatlas.ai/funds/lifeforce-capital) — Series A
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series B, Series C, Series D, Series F
- Medtronic Ventures (https://capitalatlas.ai/funds/medtronic-ventures) — Series B, Series C
- Georgian — Series C, Series D, Series F
- Mayo Clinic — Series C
- Insulet Corporation — Series C, Series D
- Samsung NEXT Ventures (https://capitalatlas.ai/funds/samsung-next-ventures) — Series C
- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Series D
- Novo Nordisk A/S — Series D
- Health Catalyst Capital Management (https://capitalatlas.ai/funds/health-catalyst-capital-management) — Series D, Series F